Marker Therapeutics (MRKR) Enterprise Value (2010 - 2026)
Marker Therapeutics (MRKR) reported Enterprise Value of -$15.6 million for Q1 2026, down 14.04% year-over-year from -$18.2 million in Q1 2025, and up 8.37% quarter-over-quarter from -$17.0 million in Q4 2025.
Marker Therapeutics (MRKR) Enterprise Value (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 17 years of Enterprise Value data on file, last reported at -$15.6 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$15.6 million, down 14.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.6 million (down 14.04% YoY), and the FY2025 annual result was -$17.0 million, up 11.2% from the prior year.
- Enterprise Value grew to -$15.6 million in Q1 2026 per MRKR's latest filing, from -$17.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$6.4 million in Q1 2023 and troughed at -$28.8 million in Q1 2022.
- A 5-year average of -$15.6 million and a median of -$15.6 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value jumped 77.79% in 2023, then sank 111.01% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$11.8 million in 2022, then dropped by 28.26% to -$15.1 million in 2023, then dropped by 27.01% to -$19.2 million in 2024, then climbed by 11.2% to -$17.0 million in 2025, then increased by 8.37% to -$15.6 million in 2026.
- Business Quant data shows MRKR's Enterprise Value at -$15.6 million in Q1 2026, -$17.0 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -584.73 Mn |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -15.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.62 Mn |
| Dec 31, 2025 | -17.04 Mn |
| Sep 30, 2025 | -18.99 Mn |
| Jun 30, 2025 | -11.81 Mn |
| Mar 31, 2025 | -13.69 Mn |
| Dec 31, 2024 | -19.19 Mn |
| Sep 30, 2024 | -9.00 Mn |
| Jun 30, 2024 | -7.80 Mn |
| Mar 31, 2024 | -11.32 Mn |
| Dec 31, 2023 | -15.11 Mn |
| Sep 30, 2023 | -17.47 Mn |
| Jun 30, 2023 | -18.10 Mn |
| Mar 31, 2023 | -6.40 Mn |
| Dec 31, 2022 | -11.78 Mn |
| Sep 30, 2022 | -18.08 Mn |
| Jun 30, 2022 | -25.80 Mn |
| Mar 31, 2022 | -28.82 Mn |
| Dec 31, 2021 | -43.50 Mn |
| Sep 30, 2021 | -48.70 Mn |
| Jun 30, 2021 | -57.20 Mn |